GENE ONLINE|News &
Pfizer Invests Nearly $2 Billion to Develop Oral GLP-1 Therapy with YaoPharma
YaoPharma will receive $150 million upfront and up to $1.935 billion in milestone payments and sales royalties. Image: freepik
Pfizer (NYSE: PFE) announced on December 9 a global exclusive collaboration with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group). The partnership focuses on the development, manufacturing, and commercialization of YP05002. It is an oral small-molecule GLP-1 receptor agonist designed for chronic weight management. YaoPharma will receive $150 million upfront and up to $1.935 billion in milestone payments and sales royalties.
Pfizer Plans to Expand Obesity and Metabolic Treatments
Chris Boshoff, Pfizer Chief Scientific Officer and President, stated, “We aim to advance this GLP-1 small molecule, expanding our obesity treatment portfolio.” The collaboration aligns with Pfizer’s strategic focus on cardiovascular and metabolic disease research, a key growth area for the company.
Under the agreement, YaoPharma will complete the ongoing Phase I trials. It grants Pfizer global exclusive rights to develop, manufacture, and commercialize YP05002. Milestone payments include development, regulatory approvals, and commercialization achievements, with additional tiered sales royalties following market approval.
Pfizer also plans combination studies of YP05002 with its Phase II GIP receptor antagonist PF-07976016 and other pipeline molecules. About a month ago, Pfizer acquired Metsera, enhancing its internal medicine portfolio with differentiated obesity candidates. Albert Bourla, Pfizer Chairman and CEO, noted that this acquisition strengthens the company’s position in one of the most high-impact and rapidly growing therapeutic areas.
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
